Aquestive Therapeutics (Aquestive Therapeutics) GF Value : $1.58 (As of Apr. 29, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-29), Aquestive Therapeutics's share price is $4.07. Aquestive Therapeutics's GF Value is $1.58. Therefore, Aquestive Therapeutics's Price-to-GF-Value for today is 2.58.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Aquestive Therapeutics is Significantly Overvalued.

Aquestive Therapeutics (NAS:AQST) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Aquestive Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	4.07	/	1.58
	=	2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquestive Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Technology Drive, Warren, NJ, USA, 07059

Website

https://www.aquestive.com

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Executives

Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki	officer: SVP, Research & Development	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung	officer: SVP, Operations	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt	officer: Chief Medical Officer	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd	officer: SVP-Operations/Value Delivery	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender	officer: SVP, General Counsel	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber	officer: SVP-Chief Strategy/Dev Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel	director, officer: Chief Innovation/Tech Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr	officer: Interim CFO
John T. Maxwell	officer: SVP-Chief Financial Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall	director, officer: President and CEO	30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta	director	C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154